{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:08Z","timestamp":1792704848546,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008382","name":"Stichting A Sister's Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF VU2015-7864"],"award-info":[{"award-number":["KWF VU2015-7864"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF VU2015-7864"],"award-info":[{"award-number":["KWF VU2015-7864"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0605-1","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T05:17:44Z","timestamp":1558502264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node"],"prefix":"10.1136","volume":"7","author":[{"given":"Kim M.","family":"van Pul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.C.L.M.","family":"Vuylsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieneke","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.","family":"te Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel J. Th.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrousjka M.","family":"van den Tol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein B.A.C.","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-8978","authenticated-orcid":false,"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"issue":"9472","key":"605_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet."},{"issue":"25","key":"605_CR2","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.2012.46.1574","volume":"31","author":"O Metzger-Filho","year":"2013","unstructured":"Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;31(25):3083\u201390.","journal-title":"J Clin Oncol"},{"issue":"15","key":"605_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"605_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1634\/theoncologist.2009-0078","volume":"14","author":"V Guarneri","year":"2009","unstructured":"Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009;14(7):645\u201356.","journal-title":"Oncologist."},{"issue":"1","key":"605_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1158\/1078-0432.CCR-11-2701","volume":"19","author":"F Andre","year":"2013","unstructured":"Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013;19(1):28\u201333.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"605_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast Cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54\u201367.","journal-title":"Cancer Discov"},{"issue":"6","key":"605_CR7","first-page":"372","volume":"13","author":"I Gingras","year":"2015","unstructured":"Gingras I, Azim HA, Ignatiadis M, Sotiriou C. Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies. Clin Adv Hematol Oncol. 2015;13(6):372\u201382.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"8","key":"605_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544\u201350.","journal-title":"Ann Oncol"},{"issue":"9","key":"605_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983\u201391.","journal-title":"J Clin Oncol"},{"issue":"4","key":"605_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"605_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nri1498","volume":"4","author":"D Gabrilovich","year":"2004","unstructured":"Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4(12):941\u201352.","journal-title":"Nat Rev Immunol."},{"key":"605_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/430394","volume":"2011","author":"N Janikashvili","year":"2011","unstructured":"Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol. 2011;2011:430394.","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"605_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nri1919","volume":"6","author":"AJ Cochran","year":"2006","unstructured":"Cochran AJ, Huang R-R, Lee J, Itakura E, Leong SPL, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6(9):659\u201370.","journal-title":"Nat Rev Immunol."},{"issue":"12","key":"605_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ejca.2009.03.024","volume":"45","author":"R Nakamura","year":"2009","unstructured":"Nakamura R, Sakakibara M, Nagashima T, Sangai T, Arai M, Fujimori T, et al. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer. 2009;45(12):2123\u201331.","journal-title":"Eur J Cancer"},{"issue":"4","key":"605_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00428-011-1145-3","volume":"459","author":"AS Mansfield","year":"2011","unstructured":"Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. Virchows Arch. 2011;459(4):391\u20138.","journal-title":"Virchows Arch"},{"issue":"4","key":"605_CR16","doi-asserted-by":"publisher","first-page":"R408","DOI":"10.1186\/bcr808","volume":"6","author":"NJ Poindexter","year":"2004","unstructured":"Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 2004;6(4):R408\u201315.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"605_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ejso.2007.05.013","volume":"34","author":"A Bembenek","year":"2008","unstructured":"Bembenek A, Li J, Loddenkemper C, Kemmner W, Stein H, Wernecke KD, et al. Presence of mature DC-lamp+ dendritic cells in sentinel and non-sentinel lymph nodes of breast cancer patients. Eur J Surg Oncol. 2008;34(5):514\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"605_CR18","doi-asserted-by":"publisher","first-page":"0904","DOI":"10.1371\/journal.pmed.0020284","volume":"2","author":"HE Kohrt","year":"2005","unstructured":"Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005;2(9):0904\u201319.","journal-title":"PLoS Med"},{"key":"605_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1471-2407-9-231","volume":"9","author":"AS Mansfield","year":"2009","unstructured":"Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, MHK L. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer. 2009;9:231.","journal-title":"BMC Cancer"},{"issue":"6","key":"605_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/cncr.21729","volume":"106","author":"K Matsuura","year":"2006","unstructured":"Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer. 2006;106(6):1227\u201336.","journal-title":"Cancer."},{"issue":"1\u20132","key":"605_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.imlet.2013.11.021","volume":"158","author":"Z Faghih","year":"2014","unstructured":"Faghih Z, Erfani N, Haghshenas MR, Safaei A, Talei AR, Ghaderi A. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett. 2014;158(1\u20132):57\u201365. 1.","journal-title":"Immunol Lett"},{"issue":"4","key":"605_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1524-4741.2000.98114.x","volume":"6","author":"RR Huang","year":"2002","unstructured":"Huang RR, Wen D, Nguyen M, Offodile R, Stern S, Turner R, et al. Selective modulation of Paracortical dendritic cells and T-Lmphocytes in breast Cancer sentinel lymph nodes. Breast J. 2002;6(4):225\u201332.","journal-title":"Breast J"},{"issue":"1","key":"605_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0002-9440(10)64152-1","volume":"161","author":"RJCLM Vuylsteke","year":"2002","unstructured":"Vuylsteke RJCLM, Van Leeuwen PA, Meijer S, PGJTB W, Statius Muller MG, Busch DH, et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol. 2002;161(1):19\u201326.","journal-title":"Am J Pathol"},{"issue":"1\u20132","key":"605_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jim.2004.04.025","volume":"291","author":"B Elliott","year":"2004","unstructured":"Elliott B, Cook MG, John RJ, Powell BWEM, Pandha H, Dalgleish AG. Successful live cell harvest from bisected sentinel lymph nodes research report. J Immunol Methods. 2004;291(1\u20132):71\u20138.","journal-title":"J Immunol Methods"},{"issue":"4","key":"605_CR25","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1084\/jem.20111457","volume":"209","author":"E Segura","year":"2012","unstructured":"Segura E, Valladeau-Guilemond J, Donnadieu M-H, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 2012;209(4):653\u201360.","journal-title":"J Exp Med"},{"issue":"9","key":"605_CR26","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1182\/blood-2011-03-344838","volume":"118","author":"R. van de Ven","year":"2011","unstructured":"Van De Ven R, Van Den HMFCM, Lindenberg JJ, Sluijter BJR, Paul a M, Leeuwen V, et al. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood. 2011;118(9):2502\u201310.","journal-title":"Blood"},{"issue":"S3","key":"605_CR27","doi-asserted-by":"publisher","first-page":"231S","DOI":"10.1007\/BF02523635","volume":"11","author":"Hans Torrenga","year":"2004","unstructured":"Torrenga H, Meijer S, Fabry H, van der Sijp J. Sentinel node biopsy in breast cancer patients: triple technique as a routine procedure. Ann Surg Oncol 2004;11(3 Suppl):231S\u2013235S.","journal-title":"Annals of Surgical Oncology"},{"issue":"1","key":"605_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-montero","year":"2009","unstructured":"Diaz-montero CM, Salem ML, Nishimura MI, Garett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastasic burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49\u201359.","journal-title":"Cancer Immunol Immunother"},{"key":"605_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016 Jul 6;7:12150.","journal-title":"Nat Commun"},{"issue":"12","key":"605_CR30","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591\u2013603.","journal-title":"Cancer Res"},{"issue":"4","key":"605_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1541-7786.MCR-08-0107","volume":"7","author":"X Hu","year":"2009","unstructured":"Hu X, Stern HM, Ge L, O\u2019Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009;7(4):511\u201322.","journal-title":"Mol Cancer Res"},{"issue":"6797","key":"605_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug;406(6797):747\u201352.","journal-title":"Nature."},{"issue":"4","key":"605_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016 Apr;13(4):228\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"605_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.0105-2896.2004.00142.x","volume":"199","author":"WR Heath","year":"2004","unstructured":"Heath WR, Belz GT, Behrens GMN, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev. 2004;199:9\u201326.","journal-title":"Immunol Rev"},{"issue":"5","key":"605_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.4161\/onci.20171","volume":"1","author":"A Pinto","year":"2012","unstructured":"Pinto A, Rega A, Crother TR, Sorrentino R. Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology. 2012;1(5):726\u201334.","journal-title":"Oncoimmunology."},{"issue":"6","key":"605_CR36","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20092618","volume":"207","author":"LF Poulin","year":"2010","unstructured":"Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen J-L, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207(6):1261\u201371.","journal-title":"J Exp Med"},{"issue":"6","key":"605_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","volume":"207","author":"SL Jongbloed","year":"2010","unstructured":"Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207(6):1247\u201360.","journal-title":"J Exp Med"},{"issue":"6","key":"605_CR38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010;207(6):1273\u201381.","journal-title":"J Exp Med"},{"issue":"11","key":"605_CR39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2326-6066.CIR-17-0110","volume":"5","author":"MFCM Hout van den","year":"2017","unstructured":"van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, et al. Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence. Cancer Immunol Res. 2017;5(11):969\u201377.","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"605_CR40","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/0008-5472.CAN-14-2386","volume":"75","author":"C Ghirelli","year":"2015","unstructured":"Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P, et al. Breast Cancer cell-derived GM-CSF licenses regulatory Th2 induction by Plasmacytoid Predendritic cells in aggressive disease subtypes. Cancer Res. 2015;75(14):2775\u201387.","journal-title":"Cancer Res"},{"issue":"22","key":"605_CR41","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1158\/0008-5472.CAN-03-3251","volume":"64","author":"RJCLM Vuylsteke","year":"2004","unstructured":"Vuylsteke RJCLM, Molenkamp BG, Gietema HA, van Leeuwen PAM, Wijnands PGJTB, Vos W, et al. Local administration of granulocyte\/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 2004;64(22):8456\u201360.","journal-title":"Cancer Res"},{"issue":"4","key":"605_CR42","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10555-010-9247-y","volume":"29","author":"MAE Watanabe","year":"2010","unstructured":"Watanabe MAE, Oda JMM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29(4):569\u201379.","journal-title":"Cancer Metastasis Rev"},{"key":"605_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.pone.0127028","volume":"10","author":"C Bergenfelz","year":"2015","unstructured":"Bergenfelz C, Larsson AM, Von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S, et al. Systemic monocytic-MDSCs are generated from monocytes and correlate with disease progression in breast cancer patients. PLoS One. 2015;10:5.","journal-title":"PLoS One"},{"issue":"10","key":"605_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00262-010-0833-1","volume":"59","author":"G Schreibelt","year":"2010","unstructured":"Schreibelt G, Tel J, Sliepen K, Benitez-Ribas D, Figdor C, Adema G, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. 2010;59(10):1573\u201382.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"605_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00262-003-0485-5","volume":"53","author":"S Satthaporn","year":"2004","unstructured":"Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother. 2004;53(6):510\u20138.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"605_CR46","first-page":"215","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev. 2012;11(3):215\u201333.","journal-title":"Nat Rev"},{"issue":"10","key":"605_CR47","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"A Seo","year":"2013","unstructured":"Seo A, Lee H, Kim E, Kim H, Jang M, Lee H, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705\u201313.","journal-title":"Br J Cancer"},{"issue":"15","key":"605_CR48","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"S Mahmoud","year":"2011","unstructured":"Mahmoud S, Paish E, Powe D, Macmillan R, Grainge M, Lee A, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast Cancer. J Clin Oncol. 2011;29(15):1949\u201355.","journal-title":"J Clin Oncol"},{"issue":"5","key":"605_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1158\/2326-6066.CIR-14-0165","volume":"3","author":"BJR Sluijter","year":"2015","unstructured":"Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R, et al. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3\/CD141+ dendritic cells and enhanced cross-presentation. Cancer Immunol Res. 2015;3(5):495\u2013505.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"605_CR50","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1158\/1078-0432.CCR-17-0944","volume":"23","author":"BD Koster","year":"2017","unstructured":"Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, et al. Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I-II melanoma: data from two randomized phase II trials. Clin Cancer Res. 2017 Oct;23(19):5679\u201386.","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0605-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:22Z","timestamp":1601055862000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0605-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0605-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The prospective observational, non-intervention cohort studies described in this manuscript were approved by the local Institutional Review Boards of the participating hospitals (VU University medical center and the Antoni van Leeuwenhoek Hospital). SLN samples were collected and handled according to medical ethical guidelines described in the \u2018Code of Conduct for Proper Use of Human Tissue of the Dutch Federation of Biomedical Scientific Societies\u2019 or protocols approved by the Institutional Review Boards of the participating hospitals with written informed consent from the patients prior to lymph node sampling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"133"}}